Issue Archive
April 2014 | Volume 13 | Issue 4
Editorials
Treatment Options in Facial and Nonfacial Volumization: An Introduction to Poly-L-Lactic Acid
Restoring Facial Volume: The Growing Impact of Poly-L-Lactic Acid
Soft tissue augmentation is an important option in aesthetic enhancement and continues to grow in popularity for a number...
Read More
Original Articles
Periorbital Hyperpigmentation: Review of Etiology, Medical Evaluation, and Aesthetic Treatment
Periorbital hyperpigmentation (POH) is a common worldwide problem. It is challenging to treat, complex in pathogenesis, and lacking straightforward and repeatable therapeutic options. It may occur in ...
Read MoreWhat Is New in Fungal Pharmacotherapeutics?
Approximately 20-25% of the population worldwide is affected by superficial cutaneous mycoses (SCM). SCM are cutaneous fungal infections with a wide array of systemic and topical treatment options. Ho...
Read MoreDyschromia in Skin of Color
BACKGROUND: Dyschromias are becoming a more common concern among patients, particularly among persons of color. There are a variety of treatments, including more novel agents for dyschromias. Evaluati...
Read MoreGender Differences in Alopecia Areata
Alopecia areata (AA) is a common, non-scarring, autoimmune hair-loss disorder with a complex genetic and environmental etiology. A higher incidence rate of AA in the female population is well describe...
Read MoreThe Skin Health and Beauty Pyramid: A Clinically Based Guide to Selecting Topical Skincare Products
The use of cosmeceuticals by patients is now commonplace. Without consultation and direction from an informed clinician, marketing pressures can lead consumers to make poor product choices that can re...
Read MorePrinciples of Topical Treatment: Advancement in Gel Vehicle Technology
Topical treatment is a pillar of dermatologic practice. The delivery of drug by a topical vehicle is dependent on complex physical chemistry and on how well patients apply the product. The potency of ...
Read MoreDiet and Acne Update: Carbohydrates Emerge as the Main Culprit
The prevalence of adult acne in the US appears to be increasing over the last few decades. But what’s behind the rise: is it nature or nurture? We are well aware that genetics can strongly influ...
Read MoreTopical Liposomal Rose Bengal for Photodynamic White Hair Removal: Randomized, Controlled, Double-Blind Study
BACKGROUND: Blond and white hair removal by laser is a complicated task with weak satisfactory results due to the deficiency in laser-absorbing chromophore.
OBJECTIVE: To investigate if repetit...
Read MoreObjective Assessment of Erythema and Pigmentation of Melasma Lesions and Surrounding Areas in Long-Term Management Regimens With Triple Combination
BACKGROUND: Melasma has a negative impact on quality of life since it typically occurs on the face.
OBJECTIVES: To evaluate the erythema and pigmentation of melasma lesions and the surrounding ...
Read MoreClinical Evaluation and Quantitative Analysis of Axillary Hyperhidrosis Treated With a Unique Targeted Laser Energy Delivery Method With 1-Year Follow Up
BACKGROUND: Primary Focal Axillary Hyperhidrosis (PHH) is a chronic disorder of excessive underarm sweat that causes significant impairment of an individual's daily activities. Multiple studies have e...
Read MoreInflammation and Acne: Putting the Pieces Together
Acne vulgaris is a common skin disease in which abnormal desquamation, excess sebum production, proliferation of Propionibacterium acnes, and production of proinflammatory mediators all contribute to ...
Read MoreEvaluating Tretinoin Formulations in the Treatment of Acne
Topical tretinoin has been a standard treatment for acne vulgaris for more than 4 decades. While tretinoin has demonstrated proven efficacy in the treatment of acne lesions, it also is associated with...
Read More
Features
Dedication and Obituary - Alan R. Shalita MD
This issue of JDD is dedicated to distinguished Professor Dr. Alan R. Shalita, longtime Chairman of the Department of Dermatology at SUNY Downstate, who was admired and beloved by the dermatology comm...
Read MoreNew and Emerging Treatments for Hyperpigmentation
The treatment of disorders of hyperpigmentation including melasma, photoaging-related dyschromia, and postinflammatory hyperpigmentation pose numerous challenges, especially in patients with higher...
Read MoreIgniting Discovery, Dialogue, and Global Innovation Through International Collaboration
Resident Rounds Part I. Program Spotlight: Department of Dermatology, Mayo Clinic
Resident Rounds is a section of the JDD dedicated to highlighting various dermatology departments with residency training programs. Resident Rounds includes three sections: (1) a program spotlight hi...
Read MoreResident Rounds Part II: Histiocytoses
Resident Rounds Part III: Multiple Myeloma Presenting as Fulminant Retiform Purpura
Retiform purpura secondary to underlying type 1 cryoglobulinemia can be a presenting sign of multiple myeloma. Severe pain may herald microvascular occlusion and impending ulceration. Recognizing the...
Read MoreNews, Views, & Reviews. Update on Antibacterial Soaps: The FDA Takes a Second Look at Triclosans
In December of 2013 the Food and Drug Administration announced it would look further into the safety and efficacy of the biocide triclosan and requested further safety data as part of a new review ...
Read MorePipeline Previews
Pipeline Previews brings to you information on the newest drugs and medical products as they become available to the dermatologic community. This department may include additional information from th...
Read MoreClinical Trial Review
Clinical Trial Review is a JDD department designed to provide physicians with information on drugs and devices undergoing clinical testing. It is our goal to inform the reader of the status of select...
Read More
Case Reports
Finasteride Associated Melasma in a Caucasian Male
Melasma is an acquired hypermelanosis that typically affects sun-exposed areas on the face and presents as symmetric brownish macules and patches. It is most commonly reported in women and thought to ...
Read MorePorphyria Cutanea Tarda in a Child Following Multi-Agent Chemotherapy
Porphyria cutanea tarda (PCT) is a blistering skin disorder that occurs most commonly in middle-aged individuals. It is caused by decreased uroporphyrinogen decarboxylase (UROD) activity, which result...
Read MoreVemurafenib-Associated Keratoses With Genetic Heterogeneity of RAS
Vemurafenib is a recently approved targeted therapy for advanced melanoma harboring the B-Raf valine-to-glutamate mutation at residue 600 (V600E). In many patients, the use of vemurafenib leads to a r...
Read More
Supplements
The Need for Consensus Recommendations on the Use of Injectable Poly-L-LacticAcid for Facial and Nonfacial Volumization
Composition and Mechanism of Action of Poly-L-Lactic Acid in Soft Tissue Augmentation
Poly-L-lactic acid (PLLA) is a synthetic, biocompatible, biodegradable polymer. For its use in soft tissue augmentation, it is supplied as a lyophilized powder containing PLLA microparticles, the siz...
Read MoreThe History Behind the Use of Injectable Poly-L-Lactic Acid for Facial and Nonfacial Volumization: The Positive Impact of Evolving Methodology
Poly-L-lactic acid (PLLA) was first approved for soft tissue augmentation in Europe in 1999 for the cosmetic correction of scars and wrinkles. Due, in part, to inadequate usage recommendations that i...
Read MoreUnderstanding, Avoiding, and Treating Potential Adverse Events Following the Use of Injectable Poly-L-Lactic Acid for Facial and Nonfacial Volumization
Injection-related adverse events (AEs) may occur with the use of any injectable substance, including all commercially available fillers. The most common of these AEs include discomfort, bruising, ede...
Read MoreSatisfying Patient Expectations With Poly-L-Lactic Acid Soft Tissue Augmentation
Patient interest and physician use of soft tissue augmentation have increased significantly in recent years, especially among younger patients. A recent consumer survey conducted on behalf of the Ame...
Read MoreConsensus Recommendations on the Use of Injectable Poly-L-Lactic Acid for Facial and Nonfacial Volumization
Poly-L-lactic acid (PLLA) was approved for use in Europe in 1999. In the United States, it was approved by the Food and Drug Administration in 2004 for the treatment of facial lipoatrophy associated ...
Read More
